The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Radiolabeled anti–prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (CRPC).
N. H. Akhtar
No relevant relationships to disclose
D. M. Nanus
No relevant relationships to disclose
S. Vallabhajosula
No relevant relationships to disclose
J. Osborne
No relevant relationships to disclose
H. Beltran
No relevant relationships to disclose
L. Tyrell
No relevant relationships to disclose
K. Nadeau
No relevant relationships to disclose
A. Saran
No relevant relationships to disclose
G. Mileo
No relevant relationships to disclose
S. J. Goldsmith
No relevant relationships to disclose
N. H. Bander
Consultant or Advisory Role - BZL Biologics
S. T. Tagawa
No relevant relationships to disclose